News & Events

• May 6, 2021
  

  C-Path Appoints Quantitative Sciences Expert as New Sr. Vice President

  Dr. Jeff Barrett will lead C-Path’s RDCA-DAP initiative focusing on rare disease data sharing and accelerating therapy development.

  TUCSON, Ariz. May 6, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jeff Barrett, Ph.D., F.C.P., as Senior Vice President and lead for its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) initiative.

• April 26, 2021
  

  C-Path Selects New Leaders of Data Science and Quantitative Medicine

  TUCSON, Ariz., April 26, 2021 — Critical Path Institute (C-Path) has named Amanda J. Borens, M.S., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC), and Jackson Burton, Ph.D., as Executive Director of C-Path’s Quantitative Medicine Program. Amanda Borens, MSc Executive Director of Data Science Borens has been with C-Path for nearly...
• April 22, 2021
  

  C-Path Opens Access to Duchenne Regulatory Science Consortium Database

  Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystrophy TUCSON, Ariz., April 22, 2021 — Critical Path Institute (C-Path) announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics...
• April 22, 2021
  

  Data Collaboration Center Request for Proposal

  RFP: The RDCA Branding & Web Portal Data Collaboration Center’s (DCC’s) platform development team is seeking a proposal, including timelines and budget, to build a user portal for our rare disease data sharing platform – Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP).   RFP: RDCA Branding & Web Portal
• April 14, 2021
  

  CPTA Welcomes Triplet Therapeutics Chief Medical Officer as Industry Co-Director

  C-Path’s Critical Path to Therapeutics for the Ataxias Consortium is pleased to announce the appointment of Irina Antonijevic, M.D., Ph.D., as the consortium’s Industry Co-Director. Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. She has gained experience...